clinical trial · NCT04552691
Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients
Chiesi Farmaceutici S.p.A.·—·approved for marketing
Fabry DiseasePegunigalsidase Alfa
brief summary
The objective of this treatment protocol is to provide guidance to Treating Physicians who seek access to pegunigalsidase alfa for Fabry patients whose clinical condition, in the opinion of the Treating Physician, requires treatment with enzyme replacement therapy (ERT) with pegunigalsidase alfa and a) cannot be adequately treated with currently approved FDA products and/or b) are not able or willing to participate in any of the on-going clinical trials in the United States.
started
—
primary completion
—
completion
—
last updated
Jul 31, 2024
official title
Expanded Access Treatment With Open-Label Pegunigalsidase Alfa for Fabry Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol